Â鶹´«Ã½¸ßÇå°æ

Academic Training

8/03-5/08 MD, College of Physicians and Surgeons, Columbia University

8/98-5/02 BS, Yale University, Major: Molecular Biophysics and Biochemistry

Professional Training

7/16-6/17 Fellowship in Molecular Genetic Pathology, New York-Presbyterian Hospital-Columbia University Irving Medical Center, New York, NY

7/13-6/14 Fellowship in Surgical Pathology, Columbia University College of Physician and Surgeons, New York, NY

7/12-6/13 Fellowship in Cytopathology, New York-Presbyterian Hospital-Weill Cornell Medical College, New York, NY

6/08-6/12 Residency in combined Anatomic/Clinical Pathology, New York-Presbyterian Hospital-Columbia University Irving Medical Center, New York, NY

American Board of Pathology Certification and State Licensure

CERTIFICATION:

2017 Molecular Genetic Pathology

2013 Cytopathology

2012 Anatomic Pathology

2012 Clinical Pathology

LICENSURE:

2009 New York State medical license (#254037)

Professional Organizations and Societies

College of American Pathologists (#1194165)

United States and Canadian Academy of Pathology (#027255)

American Society of Cytopathology (#13574)

Association for Molecular Pathology (#1291939)

Academic/Hospital Appointments

7/17-present Assistant Professor of Pathology and Laboratory Medicine, Dept. of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY

7/13-6/14 Postgraduate Clinical Fellow, Dept. of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY

Other Positions and Employment

7/14-6/16 Staff Pathologist, Dept. of Pathology, Shiel Medical Laboratory, Brooklyn, NY

7/05-6/06 Howard Hughes Medical Institute Research Training Fellow, Dept. of Pathology, Yale University School of Medicine, New Haven, CT

Publications

PEER REVIEWED ARTICLES:

1. *Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, Fazlollahi L, Stoopler MB, Sonett, JR, Sacher AG, Shu CA, Rizvi NA, Saqi A. PD-L1 Expression in Non-Small Cell Lung Carcinoma: Comparison among Cytology, Small Biopsy, and Resection Specimens. Cancer Cytopathology. In press.

2. *Heymann JJ, Mansukhani MM, Sireci AN, Yang HM, Kiran PR, Sepulveda AR. A Next Generation Sequencing Panel Aids in the Diagnosis of a Rare Collision Tumor. CAP Today. 2017, August 17; 31(8):50-51.

3. DiBardino DM, Rawson DW, Saqi A, *Heymann JJ, Pagan CA, Bulman WA. Next-generation sequencing of non-small cell lung cancer using a customized, targeted sequencing panel: Emphasis on small biopsy and cytology. Cytojournal. 2017, March 20; 14:7.

4. *Heymann JJ, Halligan AM, Hoda SA, Facey KE, Hoda RS. Fine Needle Aspiration of Breast Masses in Pregnant and Lactating Women: Experience with 28 Cases Emphasizing ThinPrep™ Findings. Diagnostic Cytopathology. 2015, Mar; 43(3):188-194.

5. *Heymann JJ, Hoda RS, Scognamiglio T. Polyclonal napsin A expression: diagnostic pitfall in distinguishing primary from metastatic tumors in the lung. Archives of Pathology and Laboratory Medicine. 2014, August; 138(8):1067-1071.

6. *Heymann JJ, Bulman WA, Maxfield RA, Powell CA, Halmos B, Sonett J, Beaubier NT, Crapanzano JP, Mansukhani MM, Saqi A. Molecular testing guidelines for lung adenocarcinoma: utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples. Cytojournal. 2014, May 22; 11:12.

7. Crapanzano JP, *Heymann JJ, Monaco S, Nassar A, Saqi A. The State of Cell Block Variation and Satisfaction in the Era of Molecular Diagnostics and Personalized Medicine. Cytojournal. 2014, March 20; 11:7.

8. *Heymann JJ, Saqi A, Turk AT, Crapanzano J. Micropapillary urothelial carcinoma: Cytologic features in a retrospective series of urine specimens. Cytojournal. 2013, Feb 28; 10:4.

9. Harigopal M, *Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome. Breast Cancer Research and Treatment. 2009, May; 115(1):77-85.

10. Costa AM, Herrero A, Fresno MF, *Heymann J, Alvarez JA, Cameselle-Teijeiro J, Garcia-Rostan G. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clinical Endocrinology. 2008, Apr; 68(4):618-634.

11. *Heymann JJ, Benson MC, O'Toole KM, Malyszko B, Brody R, Vecchio D, Schiff PB, Mansukhani MM, Ennis RD. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. Journal of Clinical Oncology. 2007, Jan; 25(1):77-84.

12. Rakoff-Nahoum S, Kuebler PJ, *Heymann JJ, Sheehy ME, Ortiz GM, Ogg GS, Barbour JD, Lenz J, Steinfeld AD, Nixon DF. Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma. AIDS Research and Human Retroviruses. 2006, Jan; 22(1):52-56.

13. Schweighardt B, Roy AM, Meiklejohn DA, Grace EJ, 2nd, Moretto WJ, *Heymann JJ, Nixon, DF. R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4+ T-cell cultures than X4 HIV-1. Journal of Virology. 2004, Sep;78(17):9164-9173.

14. Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, *Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner, LJ. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. Journal of Infectious Diseases. 2000, Sep; 182(3):766-775.

15. Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ, Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, *Heymann JJ, Zhang L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. Journal of Clinical Investigation. 1999, Sep; 104(6):R13-18.

ABSTRACTS:

1. Lee JM, Kim JS, *Heymann JJ, Pagan C, Crapanzano J, Fazlollahi L, Haghighi M, Stoopler MB, Sonett JR, Sacher AG, Shu CA, Rizvi NA, Bulman WA, Saqi A. Feasibility of PD-L1 expression testing in non-small cell lung cancer from EBUS-TBNA samples. Poster at: American Thoracic Society International Conference; Washington, DC.

2. Kim JS, *Heymann JJ, Pagan C, Crapanzano J, Fazlollahi L, Haghighi M, Bulman WA, Saqi A. Feasibility of PD-L1 expression testing in non-small cell lung cancer from pleural and pericardial effusion samples. Poster at: American Thoracic Society International Conference; Washington, DC.

3. *Heymann JJ, Pagan C, Crapanzano J, Fazlollahi L, Haghighi M, Bulman W, Stoopler M, Sonett J, Sacher A, Shu C, Rizvi N, Saqi A. PD-L1 Expression in Non-Small Cell Lung Carcinoma: Feasibility of Cytology and it Comparison with Resection and Small Biopsies. Poster at: United States and Canadian Academy of Pathology Annual Conference; San Antonio, TX.

4. *Heymann JJ, Mansukhani MM, Sireci AN, Yang HM, Kiran PR, Sepulveda A. Next Generation Sequencing Panels Aid in the Diagnosis of Rare Collision Tumors. Presentation at: Association for Molecular Pathology Annual Meeting; Charlotte, NC.

5. *Heymann JJ, Singh B, Durham BH, Mansukhani MM, Crapanzano JP, Saqi A. Manual and Laser Capture Microdissection: Optimizing EGFR Molecular Testing in Small Biopsies and Cytology Specimens. (March, 2014). Poster at: United States and Canadian Academy of Pathology Annual Conference; San Diego, CA.

6. *Heymann JJ, Halligan AM, Hoda SA, Facey KE, Hoda RS. Fine Needle Aspiration of Breast Masses in Pregnant and Lactating Women: ThinPrep™ Appearance of Lactating Adenoma. (November, 2013). Poster at: American Society of Cytopathology Annual Scientific Meeting; Orlando, FL.

7. *Heymann JJ, Saab J, Zachariah J, Hoda RS. EGFR and KRas Mutation Analysis in Lung Adenocarcinoma: Adequacy of Cytology Samples. (March, 2013). Poster at: United States and Canadian Academy of Pathology Annual Conference; Baltimore, MD.

8. *Heymann JJ, Hoda RS, Scognamiglio T. (March, 2013). Analysis of Napsin A Expression in Mucinous Lung Tumors on Histological and Cytological Specimens. Poster at: United States and Canadian Academy of Pathology Annual Conference; Baltimore, MD.

9. *Heymann JJ, Bulman WA, Maxfield RA, Powell CA, Halmas B, Stoopler M, Sonett J, Beaubier NT, Babiac AM, Borczuk, Murty VV, Mansukhani MM, Saqi A. (March, 2012). Molecular Testing For Lung Adenocarcinoma: Concordance Between Cytology and Histology. Poster: United States and Canadian Academy of Pathology Annual Conference; Vancouver, BC.

10. Bulman W, *Heymann JJ, Mansukhani M, Maxfield R, Saqi A. (May, 2011). Molecular Testing for Lung Adenocarcinoma Using EBUS-TBNA Cytology: Concordance Between Cytology and Histology. Poster at: American Thoracic Society International Conference; Denver, CO.

11. *Heymann JJ, Turk AT, Saqi A, Crapanzano JP. (March, 2011). Cytologic features of micropapillary urothelial carcinoma in exfoliative urinary specimens. Poster at: United States and Canadian Academy of Pathology Annual Conference; San Antonio, TX.

12. Turk AT, *Heymann JJ, Crapanzano, JP, Saqi, A. (March, 2011). Endocervical Adenocarcinoma In Situ and Invasive Adenocarcinoma: The Significance of HPV-DNA results. Poster:United States and Canadian Academy of Pathology Annual Conference;San Antonio, TX.

13. *Heymann JJ, Rimm DL. (May, 2006). Assessment of the ras-raf pathway in papillary carcinoma of the thyroid: toward construction of a model for prediction of recurrence. Presented at: HHMI Meeting of Medical Fellows; Bethesda, MD.

14. Ennis RD, *Heymann JJ, Schiff PB, Benson MC, Mansukhani MM, O'Toole KM. (March, 2005). Prospective phase II trial of androgen deprivation (AD) to maximal response followed by external beam radiotherapy (RT) with continued AD for a total of 9 months: efficacy and preservation of potency. Poster at: ASCO Prostate Cancer Symposium; Orlando, FL.

15. Schweighardt B, Roy AM, Meiklejohn DA, Grace EJ, 2nd, Moretto WJ, *Heymann JJ, Nixon DF. (March, 2003). CD3/CD28 costimulated CD4+ T cells are highly susceptible to infection by X4, R5, and primary strains of HIV-1. Poster at: Keystone Symposium on HIV Pathogenesis; Banff, Al.

16. Schweighardt B, Roy AM, Meiklejohn DA, Grace EJ, 2nd, Moretto WJ, *Heymann JJ, Nixon, DF. (March, 2003). Infectivity and cytopathicity of HIV-1 is greatly affected by the purification state of the virus. Poster at: Keystone Symposium on HIV Vaccine Development; Banff, Al.

OTHER NON-PEER REVIEWED ARTICLES:

16. Heymann JJ, Ennis RD. High-risk localized prostate cancer treated with neoadjucant androgen deprivation to maximal response followed by external beam radiotherapy with concomitant and adjucant androgen deprivation for a total of 9 months in a phase II trial: a case report. American Journal of Hematology-Oncology. 2007, Apr; 6:1-4.